A Phase 2 interventional study of Methadone in Fibroid Uterus, sponsored by Johns Hopkins University. Recruiting at 2 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-12.
Sponsored by Johns Hopkins University · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 156 studies in Leiomyoma with a site in United States — 19 open to participants now, 29 under way, 3 of them phase 3. Leiomyoma · United States.
Among the 156 studies in Leiomyoma with a site in United States, this one is the 34th largest by planned enrollment of the 121 interventional ones that give a count, is one of 8 that started in 2025, is one of 19 in phase 2, reaches primary completion later than 13 of the 27 other live ones, and was the 144th registered.
439 studies on the registry are indexed under Leiomyoma; 74 are open to participants now.
Browse Leiomyoma studies →19 of the 156 studies in Leiomyoma with a site in United States are open now. Recruiting first, the newest first:
Christiana Care Health Services · Sites in United States
Ages 18+ · Women only
Northwestern University · Sites in United States
Ages 18–50 · Women only
Medstar Health Research Institute · Sites in United States
Ages 18+ · Women only
Thomas Jefferson University · Sites in United States
Ages 18+ · Women only
Joseph Findley MD · Sites in United States
Ages 18–45 · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 44 Leiomyoma studies recruiting now, 23 (52%) set no upper age limit and 20 (45%) stop at 75 or younger; 4 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
156 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 21 · Phase 3 32 · Phase 4 17
First in 1995; this study’s year is marked. 8 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 66 across 307 interventional studies indexed under Leiomyoma.
Median enrollment 57 across the 121 interventional studies, 187 across the 34 observational. Of the 113 that completed or were terminated, 59 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
71 of 156 have an industry lead sponsor. The 10 most frequent:
Johns Hopkins University is the lead sponsor of 1,817 studies on the registry; 316 are open to participants now.
Of its 208 completed or terminated interventional studies of FDA-regulated products, 144 (69%) have results posted.
Johns Hopkins University has 3 studies filed under Leiomyoma — fewer than ten, so there is no comparison to draw.
10 of the studies in Leiomyoma with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07078682Zenchi, Inc.An Open-Label Study to Evaluate the Effect of Elix Cycle Balance & Elix Daily Harmony on Fibroid-related Symptoms | 2026-11 |
| NCT07286188Northwestern UniversityEffect of Misoprostol on Fluid Deficit Volume in Hysteroscopic Myomectomy | 2026-12 |
| NCT06536517Johns Hopkins UniversityThe Effects of One-time Intraoperative Methadone During Laparoscopic Hysterectomy in Reducing Opioid Prescription. | 2026-12 |
| NCT04126824University of California, Los AngelesEffect of Addition of Steroids on Duration of Analgesia | 2026-12-30 |
| NCT05386615InSightecPost-Exablate Pregnancy Outcomes Registry Study: Exablate Treatment of Symptomatic Uterine Fibroids | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 156 studies in Leiomyoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Currently, there is a nationwide epidemic of opioid abuse and overdose deaths. One source of excess opioids is overprescribing in the postoperative period. This study aims to find the optimal pain medication plan during and after laparoscopic hysterectomy to eliminate long-term opioid use.
Given the increasing opioid abuse and over-prescription post-operatively, an effort should be made to determine whether one time dosing of Methadone, a longer opioid analgesics, intra-operatively is an adequate potential in treating postoperative pain after hysterectomy surgeries. The investigators hypothesize that this could minimize the need for additional post-operative and outpatient opioid prescriptions and decrease the adverse effects that are associated with the consumption, including new opioid abuse.
Intervention group will receive methadone intraoperatively while the other group would receive short-acting opioids (standard).
Problem:
The relief of moderate to severe postoperative pain in surgeries including abdominal surgeries continues to pose a major therapeutic dilemma. The traditional and most common therapy is the administration of short-acting opioid analgesics, intra-operative and post-operative, at intervals every 3-4 hours. However, the use of opioids with relatively short plasma half-lives at varying intervals may lead to various fluctuating drug concentrations in plasma, and side effects including respiratory, longer hospitalizations, delayed ambulation, inadequate pain relief and potential avenues for abuse. Identifying a more efficient and safer therapy for intraoperative pain analgesia can be helpful in controlling pain requirements in the post-operative setting.
In major inpatient and ambulatory surgeries, intraoperative single-dose methadone, through its unique pharmacology, has been shown to produce better analgesia, reduce opioid use and minimize adverse side effects compared with conventional repeated dosing of short-duration opioids. Additionally, methadone is theorized to be an N-methyl-D-aspartate (NMDA) receptor noncompetitive antagonist, which may contribute to its increase in analgesic potential as compared with fentanyl analogues. Finally, it has been shown to improve ambulation in the post operative anesthesia setting and pain control in chronic pain patients. The study of intra-operative methadone has not been extensively studied for gynecology surgeries, but one study has shown the decrease of mean opioid consumption post operatively after receiving one dose of intra-operative methadone compared to shorter acting opioids in same-day laparoscopic myomectomy. Given the increasing opioid abuse and over-prescription post-operatively, an effort should be made to determine whether one time dosing of longer opioid analgesics intra-operatively is an adequate potential in treating postoperative pain after hysterectomy surgeries and could minimize the need for additional post-operative and outpatient opioid prescriptions.
This study aims at addressing the requirement for postoperative opioid prescription after intraoperative longer acting vs shorter acting opioids in laparoscopic hysterectomy.
Hypothesis:
Single dose of intra-operative methadone is an adequate potential in treating post-operative pain after laparoscopic total hysterectomy surgeries, reducing the additional need for post-operative and outpatient opioid prescriptions and decreasing the adverse effects associated with opioid consumption.
Importance of research:
Given the increasing opioid abuse and over-prescription post-operatively, an effort must be made to determine whether one time dosing of longer opioid analgesics intraoperatively in conjunction with non-opioid multimodal medications is adequate to treat postoperative pain after laparoscopic hysterectomy. Additionally, this intervention may decrease the need for additional prescriptions or unscheduled patient contacts.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intra-operative single dose IV Methadone (0.25 mg/kg of ideal body weight)
Drug: Methadone
Standard intra-operative IV shorter acting opioids
Drug: Methadone
Intra-operative single dose IV Methadone (0.25 mg/kg of ideal body weight)
Total post-operative opioid requirements in oral morphine milligram equivalents (MME)
Total post-operative opioid requirements in oral morphine milligram equivalents (MME) in first 7 post operative days.
Time frame: 1 week
Mobility and satisfaction of analgesia
Mobility and satisfaction of analgesia on post-operative day one and seven (binary question Y/N)
Time frame: Post operative day 1, Post operative day 7
Number of unplanned returns to emergency room/clinic or patient initiated phone call regarding pain
Time frame: 1 week
Overall satisfaction with pain control
0-10 scale (0- no pain, 10-worst pain)
Time frame: 1 week
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2025 (actual). Primary completion is estimated for Dec 2026, 21 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Methadone